3rd annual Tumour Models, London, UK

Harness Clinically Relevant Cancer ModelsImprove Predictability & Translatability of ResearchSmartly Interpret to Ensure Clinical Trial Efficacy

EXPERT SPEAKERS INCLUDE:

Anderson Ryan Senior Group Leader in Radiation Oncology University of Oxford

Sabine Hoves Senior Scientist, Discovery Oncology Roche

Edward Rosfjord Principal Research Scientist Pfizer

Manuel Hidalgo Vice Director of Translational Research, Clinical Research Programme Director Spanish National Cancer Research Centre (CIOCC)

Rajendra Kumari CSO PRECOS Ltd, A Crown Bioscience Company

Neal Goodwin VP Corporate Research & Development Champions Oncology

LEAD PARTNER:

Nicola McCarthy Oncology Program Manager Horizon Discovery

Barry Davies Principal Scientist AstraZeneca

Hazel Jones Head of Combination Therapies, Drug Development Office Cancer Research UK

RESEARCHED & DEVELOPED BY:Tel: +44 (0)203 141 8700 | Email: [email protected]

www.tumour-models.com

PROGRAMME PARTNER: SPOTLIGHT PARTNER:

Tumour Models London 2nd-4th December 2014

2nd-4th December 2014 | London


Tel: +44 (0)203 141 8700 Email: [email protected]

tumour-models.com Tumour Models

1 6

3 8

2 7

4 9

5 10

BENEFITS OF ATTENDING

Increase Clinical Trial Success RatesWith Predictive Tumour ModelsFail Smartly and Learn Fast: Harness Physiologically Relevant Tumour Models to Optimise Translational Research into Clinical Value

With the Tumour Models Community gathering real momentum in 2014 after the 3rd Tumor Models Boston Summit, join the 4th Tumour Models Summit in London to gain unpublished data from case studies, where you will discover how clinically relevant tumour models are being applied to better predict drug efficacy action within patient subgroups.

You will benefit from an in-depth focus on cutting edge in vivo and in vitro modelling best practice, and discover the movement towards more physiologically relevant models that better mimic the tumour environment, represent the patient population and help you prioritise drug candidates.

This is the opportunity for you to collaborate with other preclinical oncologists and translational researchers to uncover novel emerging models and effective preclinical strategies to only advance your most promising candidates.

Exchange knowledge to improve the interpretation of your data derived from tumour model studies and reduce failure rates of oncology clinical trials.

Leave inspired with new ideas, tools and connections to maximise the potential of your discoveries.

Discover the latest developments for clinically relevant tumour models in preclinical trials to enhance your drug development

Harness in vitro modelling to investigate mechanisms of drug resistance that better represent response to therapy

TOP 10 REASONS TO ATTEND TUMOUR MODELS LONDON 2014:

Learn about the most innovative immuno-competent in vitro and in vivo models being used in the development of cancer-immunotherapies

Explore how establishing a preclinical model network can enhance the development of combination therapies

Harness PDX models to improve the representation of the patient population and enhance translational decision making

Discover the technological advancements in the field of preclinical tumour modelling and improve your preclinical predictions

Discover the emergence of 3D modelling in drug candidate development to specifically target the tumour microenvironment

Learn how applying next generation sequencing can improve the development of personalised cancer therapies

Explore the advanced pharmaco-imaging technology being used to monitor the pharmacokinetics in tumour models and improve drug efficacy

Understand the importance of enhancing translational collaborations to improve drug discovery, efficacy testing and overall translational success

SPEAKER FACULTY




Neal Goodwin VP Corporate Research & Development Champions Oncology

William Shingler Development Project Manager Immunocore

Stefanie Mullins Scientist I MedImmune

Nicola McCarthy Oncology Program Manager Horizon Discovery

Anderson Ryan,Senior Group Leader in Radiation Oncology University of Oxford

Barry Davies Principal Scientist AstraZeneca

Frances Richards Pharmacology & Drug Development Group Lab Head Cancer Research UK Cambridge Institute

Els Hermans Research Manager PDTX Platform University Hospital Leuven

Sue Eccles Professor of Experimental Cancer Therapeutics Institute of Cancer Research

Edward Rosfjord Principal Research Scientist Pfizer

Louise Jones Professor of Breast Pathology Barts Cancer Institute

Aaron Cranston Head of in vivo Pharmacology MISSION Therapeutics

Thomas Pöschinger Preclinical Imaging Scientist, Discovery Oncology, pRED Roche

Sabine Hoves Senior Scientist, Discovery Oncology Roche

Hazel Jones Head of Combination Therapies, Drug Development Office Cancer Research UK

Outstanding meeting with first class speakers. I learned a lot and I will certainly recommend the meeting to my colleagues Sanofi Aventis

Manuel Hidalgo Vice Director of Translational Research, Clinical Research Programme Director Spanish National Cancer Research Centre (CIOCC)

Rajendra Kumari CSO PRECOS Ltd, A Crown Bioscience Company




WORKSHOP A

WORKSHOP B

Through this interactive peer to peer session you will learn:• How to generate and characterise preclinical models for the development of combination

therapies • What are the current advantages and limitations of the preclinical models used in the

discovery of combination therapies • How to identify and implement these models to enhance preclinical predictions• The application of GEMM models within combination therapy development

From this in-depth session you will take away:• The main advantages of PDX models over standard Xenograft models in optimising translational

decision making • Application of xenograft models to predict patient response and prioritise which candidates to progress in phase II

patient studies• How to harness and refine PDX models for proof of confidence studies and enhance predictability of preclinical

studies• How to use PDX models to overcome dosage selection and toxicology challenges, in order to enhance the

translational outcomes• How the use of PDX models in preclinical research using can improve clinical trial design

Dr Hazel Jones is head of combination therapies Cancer Research UK. Hazel has extensive experience in developing preclinical models and is currently collaborating with leading UK researchers to discuss how to make models more accessible for translational research across the UK.

Workshop leaderHazel JonesHead of Combination Therapies, Drug Development OfficeCancer Research UK

Establishing a Network of Preclinical Models to Enhance the Development of Combination Therapies Date: Tuesday 2nd December 2014 | Time: 9.00am – 12.00pm

Developing and Harnessing Patient Derived Xenograft (PDX) Models to Better Demonstrate Drug Efficacy Action and Improve Translational Decision Making Date: Tuesday 2nd December 2014 | Time: 1.00pm – 4.00pm

Workshop leaderBarry DaviesPrincipal ScientistAstraZeneca

Dr Barry Davies is a Principal Scientist in Oncology Innovative Medicines at AstraZeneca.Barry has expertise in cancer cell biology, and wide experience of drug discovery and early development from target selection to Phase 2 proof of concept studies.




8.00 Registration & Breakfast

9.00 Chairman’s Opening Remarks

Model into Human: The Preclinical Holy Grail

9.10 Conversations That Matter: Developing and Utilising a Selection of Truly Predictive ModelsEavesdrop on exclusive one-to-one interviews with key opinion leaders, who are leading the way to improve the predictability and translational success of preclinical oncology research:

• What are the current limitations in clinically-relevant preclinical models?

• Is the industry seeing any clinical success stories using novel models?

• Are we designing the right models and using these models to ask the right questions?

Edward Rosfjord, Principal Research Scientist, Pfizer Anderson Ryan, Senior Group Leader in Radiation Oncology University of Oxford

Modelling for Immunotherapeutic Drug Discovery

10.00 De-Risking Late Stage Development: Optimising Translational Research for Clinical Value• Human surrogate clinical trials: Utilising large portfolios of

models to accurately represent patient population

• Enhanced in vivo models for the development of immune-therapeutics

Rajendra Kumari, CSO, PRECOS Ltd, A Crown Bioscience Company

10.30 Speed Networking & Morning Refreshments

11.30 Syngeneic Mouse Models in Onco-Immunology and How They Translate into Clinical Trials• Relevance of syngeneic mouse models for prediction

of changes in the tumour infiltrate after treatment with immunotherapies

• Analysing the myeloid immune cell infiltrate in syngeneic tumour models

Sabine Hoves, Senior Scientist, Discovery Oncology, Roche

12.00 Development of T Cell Receptor-Based Biologics: An in vitro Route to the Clinic

• Clinical experience: How predictive was the IMCgp100 in vitro toxicity and efficacy package?

• Enhancing ImmTAC preclinical specificity testing: A lesson learned

William Shingler, Development Project Manager, Immunocore

A Movement Towards Physiologically Relevant Models

12.30 Definitive and Controlled Preclinical Model Systems Through the Use of Isogenic Cell Lines

• Combining knowledge of tumour biology and microenvironment with cell lines to predict drug action

Nicola McCarthy, Oncology Program Manager, Horizon Discovery

12.45 Networking Lunch

2.00 Models for Targeted Therapies for Disseminated Disease

• Challenges of target validation and drug development in invasion and metastasis: 3D in vitro functional assays

• Getting the most out of human tumour xenografts

Sue Eccles, Professor of Experimental Cancer Therapeutics, Institute of Cancer Research

2.30 Multicellular 3D in vitro Models to Study Disease Progression and the Impact of the Microenvironment

• Generating appropriate cell populations to study normal, pre-malignant and malignant disease

• Capturing the heterogeneity of cancer

Louise Jones, Professor of Breast Pathology, Barts Cancer Institute

Personalised & Heterogeneous Models for Enhanced Drug Efficacy

3.00 Patient Specific and Clinically Relevant PDX Programme for Clinical Advancement

• Application of PDX models to improve preclinical predictions and optimise translational decision making

Neal Goodwin, VP Corporate Research & Development, Champions Oncology

3.30 Afternoon Refreshments

4.00 Preclinical Tumour Models: Their Role in our Mission from Drug Discovery to Clinical Practice• How do we and how should we interpret the data?

• Planning for success: The path from bench to bedside (and the models in between)

Aaron Cranston, Head of in vivo Pharmacology, MISSION Therapeutics Ltd

4.30 Tumour Model Breakout RoundtablesThe Tumour Models speaker faculty is second to none, but there is just as much knowledge in the audience as there is onstage. Tap into your peers’ wealth of expertise on key issues during Breakout Roundtables:

1. How do we validate PDTX models for histologic and genetic profiling?

2. Do current models address the key issues, and what about animal ethics?

3. How to implement the most accurate in vitro models to compliment in vivo studies

4. How to use the combination of NGS and tumour modelling to better represent the patient population

5. How to optimise PDX models to predict efficacy of ADCs

Els Hermans, Research Manager PDTX Platform, University Hospital Leuven Sue Eccles, Professor of Experimental Cancer Therapeutics, Institute of Cancer Research

5.30 Chair’s Closing Remarks

5.40 Close of Day 1

CONFERENCE DAY 1 - Wednesday 3rd December 2014

Keynote Session Interactive Session Networking Session




8.00 Breakfast

9.00 Chairman’s Opening Remarks

Translatability: Interpreting Data into the Clinic

9.10 Reverse Translation: Using Preclinical Studies to Better Understand Emerging Clinical Data

• Understanding how preclinical studies are crucial in guiding patient and biomarker selection strategies and clinical developments

• How preclinical studies are critical to our understanding of emerging clinical data

• Their importance in redefining clinical plans as more opportunities in new disease settings are discovered

Anderson Ryan, Senior Group Leader in Radiation Oncology University of Oxford

9.40 Integrating NGS and Avatar Mouse Models in Personalised Cancer Treatment• How avatar models have been utilised in personalised

medicine programmes and crucially what are the main advantages and limitations of this approach

Manuel Hidalgo, Vice Director of Translational Research, Clinical Research Programme Director, Spanish National Cancer Research Centre (CIOCC)

10.10 Enhancing Both in vitro and in vivo Modelling for the Development of Combination Immunotherapies • To discuss the use of in vitro models in the development of

small molecular inhibitors

• How the combination of different in vivo models can enhance the discovery of new immunotherapies

Stefanie Mullins, Scientist I, MedImmune

10.40 Morning Refreshments

11.10 Application of Non-Invasive Imaging Technologies to Monitor Pharmacodynamic Effects in Orthotopic Cancer Models• Applying bioluminescence and fluorescence imaging

• Micro-computed tomography and the combination thereof in several orthotopic tumour models, e.g. brain, breast, and lung cancer

Thomas Pöschinger, Preclinical Imaging Scientist, Discovery Oncology, pRED, Roche

11.40 Application of Xenograft Models to Predict Patient Response and Prioritise Schedule of the AKT Inhibitor AZD5363 in Patients

• How to use a predictive PK-PD-efficacy modelling approach in xenografts to compare the relative efficacy of three different schedules of AZD5363

• How has this been applied to prioritise which schedule to take forward into phase II in patients

Barry Davies, Principal Scientist, AstraZeneca

12.10 Understanding the Importance and Application of PDX Models to Improve Preclinical Predictions and Optimise Translational Decision Making

• How PDX models can optimise biomarker identification and

validation

• How PDX models can better represent tumour heterogeneity present with the patient population

Edward Rosfjord, Principal Research Scientist, Pfizer

12.40 Networking Lunch

Overcoming Resistance Mechanisms & Modelling for Combination Therapies

2.00 An in vitro Co-Culture Model of Pancreatic Cancer for Investigation of Drug Resistance and Efficacy

• Description of the development of an in vitro co-culture model of pancreatic ductal adenocarcinoma

• Identification of chemo-resistance in the model

Frances Richards, Pharmacology & Drug Development Group Lab Head, Cancer Research UK Cambridge Institute

2.30 Harnessing a Preclinical Model Network for Effective Combination Therapy Screening

• Modelling to test efficacy for combination therapies

• Predicting the impact of combination therapies on the tumour

Hazel Jones, Head of Combination Therapies, Drug Development Office, Cancer Research UK

Enhancing Translational Collaborations

3.00 Interactive Solution Finding Session: How to Enhance Both Internal and External Collaborations to Enhance Drug Discovery, Efficacy Testing and Translational Success

Tumour models are only as good as the data derived from them and how it is interpreted to influence translational and clinical decisions. This session will discuss and debate how:

• Communication can be improved between preclinical and clinical teams

• To ensure preclinical data positively impacts translational decisions and clinical trial design

• Public private partnerships are leveraging external expertise

3.30 Afternoon Refreshments

4.00 Roundtable Intelligence & Mastermind DiscussionMissed a roundtable you wished you were at or have unanswered questions to your specific challenges? Fear not as roundtable moderators summarise the key industry intelligence from the earlier discussions, providing you one final opportunity to outline key future trends for the field

• How can the field reinvigorate the negative mind-set facing cancer drug development to overhaul high clinical attrition rates?

• What are the future trends for cancer drug discovery and efficacy testing?

• How can we, as the Tumour Models community, implement key solutions to affect positive change and foster innovation?

4.30 Chair’s Closing Remarks

4.40 Close of Congress

CONFERENCE DAY 2 - Thursday 4th December 2014

Keynote Session Interactive Session Networking Session




SPONSORS

JOIN THE TUMOUR MODEL COMMUNITY:

Contact

Diane McKenna Commercial Director, Tumour Models


Lead Partner – Crown Bioscience

Crown Bioscience provides Translational Platforms focused on fast-tracking candidates to identify biomarkers and patient responders based on the pharmacological response of human surrogate models. Power your Drug Discovery using the world’s largest commercial collection of well-characterised PDX in passage (HuPrime) plus a curated, searchable database of patient, genotypic and phenotypic data as well as pharmacological response (HuBase). Identify potential biomarkers (HuSignature™) based on pharmacological response or use your biomarker signature to identify models available for screening to confirm patient responder and non-responder populations (HuTrials™). Fast forward your discovery programmes today. www.crownbio.com

Programme Partner – Champions Oncology

Champions Oncology was founded by renowned specialists in the field of cancer diagnosis, treatment, and research. The Champions Oncology team is comprised of seasoned oncology professionals passionately dedicated to working to accelerate oncology drug development, improve treatment outcomes and extend lives. Our core platform, the Champions TumorGraft™ offers an enhanced xenograft mouse avatar model for growing and testing human tumours. Champions Personalized TumorGrafts™ empower patients and physicians using an in vivo xenograft mouse avatar based diagnostic model that has shown to be predictive of a patients’ clinical response to cancer treatments and anticancer therapies.

www.championsoncology.com

Tumour Models London is proud to partner with:

LEAD PARTNER PROGRAMME PARTNER

Spotlight Partner – Horizon Discovery

Horizon Discovery combines long scientific heritage in translational research with GENESIS™, a precision gene editing platform incorporating rAAV, CRISPR and ZFN technologies. Horizon supplies genetically-defined cell lines, gene-editing tools and services, custom cell line generation, molecular reference standards, and contract research services to approaching 1,000 academic, clinical and biopharmaceutical organisations.

www.horizondiscovery.com

SPOTLIGHT PARTNER A very enjoyable meeting. Very

interesting to hear how other

companies are using in vivo models

and their thought processes. Sanofi

Code: 4531

* All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216

TERMS & CONDITIONS

VENUE AND ACCOMMODATION:

REGISTER EVENT PRICES

PRICING & VENUE

STANDARD PRICES

PACKAGERegister & Pay before 22nd August

Register & Pay before 26th September

Register & Pay before 31st October Standard Price

CONFERENCE + 2 WORKSHOPS

£2197 +VAT (save £800)

£2397 +VAT ( save £600)

£2597 +VAT (save £400)

£2797 +VAT (save £200)

CONFERENCE + 1 WORKSHOP

£1698 +VAT (save £700)

£1898 +VAT (save £500)

£2098 +VAT (save £300)

£2298 +VAT (save £100)

CONFERENCE ONLY£1199 +VAT (save £600)

£1399 +VAT (save 400)

£1599 +VAT (save £200) £1799 +VAT

HALF DAY WORKSHOP

£599 +VAT

ACADEMIC / NOT FOR PROFIT PRICES

PACKAGERegister & Pay before 22nd August

Register & Pay before 26th September

Register & Pay before 31st October Standard Price

CONFERENCE + 2 WORKSHOPS

£1318.20 +VAT £1438.20 +VAT £1558.20 +VAT £1678.20 +VAT

CONFERENCE + 1 WORKSHOP

£1018.80 +VAT £1198.80 +VAT £1258.80 +VAT £1378.80 +VAT

CONFERENCE ONLY £719.40 +VAT £839.40 +VAT £959.40 +VAT £1079.40 +VAT

HALF DAY WORKSHOP

£359.40 +VAT

*VAT is charged at 20%




Venue: This modern and luxurious Kensington hotel offers a relaxed environment in the heart of London. Hotels in Kensington with such charm and supreme comfort are rare. The Millennium Gloucester Hotel London Kensington effortlessly combines a convenient location with a unique sense of style and character.

This hotel is perfectly positioned for visiting many of the British capital’s greatest attractions. They include nearby Hyde Park, the Royal Albert Hall, Kensington Palace, the Natural History Museum and the Victoria and Albert Museum.

Millennium Gloucester Hotel London Kensington 4-18 Harrington Gardens London SW7 4LH

Accommodation: Overnight accommodation is not included in the registration fee, however accommodation options will be sent out with your confirmation email upon registering.

Tumour-models.com/register Tel: +44 (0)203 141 8700 Email: [email protected]

Mail: Hanson Wade 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU

• 10% discount – 3 delegates • 15% discount – 4 delegates • 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

TEAM DISCOUNTS*

3rd annual Tumour Models, London, UK

Health & Medicine

Transcript of 3rd annual Tumour Models, London, UK